FDA approves KalVista’s Ekterly for hereditary angioedema
The FDA has approved Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE).
The FDA has approved Ekterly (sebetralstat) as the first and only oral on-demand medication for acute attacks of hereditary angioedema (HAE).
What's Your Reaction?
